Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Third, the compound has shown a favorable safety profile in preclinical studies
If you experience any of these symptoms, its best to speak with a doctor to determine the cause and discuss whether a B12 injection is necessary
If those pages do not work and you believe you are receiving this message in error, please reach out to [email protected].
PubMed ID: 11146367 Heffernan MA et al
No.:GL-VL-0109 CAS CAS:N/A Formula:Lyophilized MW:Variable (polymeric) Batch No.:QC2026-VL0109-9980 Mfg Date:2026-02-16 Test Date:2026-02-20 Sample Wt.:44.3 mg Appearance:White lyophilized powder in sealed vials Storage:2-8C, protect from light Spec.: Q/SH-VL-2026 Analytical Method & Instrumentation Method:Reversed-Phase HPLC (USP , ChP 0512) Instrument:Agilent 1260 Infinity II HPLC System (SN: DE30949) Column:Agilent ZORBAX Eclipse Plus C18, 2504.6mm, 5m (Lot: B75522) A Mobile Phase A:0.1% Trifluoroacetic acid (TFA) in Milli-Q Water (18.2 Mcm) B Mobile Phase B:0.1% TFA in Acetonitrile (HPLC Grade, Fisher Scientific) Gradient:0min5%B, 5min20%B, 20min60%B, 28min95%B, 30min95%B / Flow/Temp:1.0 mL/min / 30.0 0.5C (thermostatted) Detection:UV-DAD at 220nm (bandwidth 4nm, ref 360nm) Injection:20 L, sample conc
Side effects include abdominal pain and discomfort, oily or fatty stools, gas
